Targeting Cell Survival Pathways to Enhance Response to Chemotherapy

— —

Benjamin Bonavida (Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USA) Daniel E. Johnson (Professor, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, USA)

Targeting Cell Survival Pathways to Enhance Response to Chemotherapy

Benjamin Bonavida (Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USA), Daniel E. Johnson (Professor, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, USA)

$299.95

Hardback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Academic Press Inc
28 March 2018

Biotechnology industries; Personal & public health; Oncology

Series: Cancer Sensitizing Agents for Chemotherapy

Targeting Cell Survival Pathways to Enhance Response to Chemotherapy encompasses recently developed molecular targeting agents and approaches that suppress cell survival signaling. Cell survival signaling attenuates the effectiveness of conventional chemotherapy and numerous mechanisms have been described, and continue to be described, which contribute to cell survival in the face of chemotherapy treatment.

Key pathways leading to chemoresistance emanate from growth factor receptors, PI3K, STAT3, anti-apoptotic Bcl-2 family members, autophagy, and the DNA damage response pathway. New advances have underscored the potential of targeting each of these cell survival mechanisms to improve responsiveness to chemotherapy. This book reviews these recent advances and provides a foundational background and hints of new opportunities for basic, translational, and clinical investigators focused on improving therapeutic responses to chemotherapy.

Series edited by: Benjamin Bonavida (Professor Department of Microbiology Immunology and Molecular Genetics David Geffen School of Medicine University of California USA)
Volume editor: Daniel E. Johnson (Professor Department of Otolaryngology-Head and Neck Surgery University of California San Francisco USA)
Imprint: Academic Press Inc
Country of Publication: United States
Dimensions: Height: 235mm, Width: 191mm,
Weight: 770g
ISBN: 9780128164327
ISBN 10: 0128164328
Series: Cancer Sensitizing Agents for Chemotherapy
Pages: 308
Publication Date: 28 March 2018
Audience: Professional and scholarly , Undergraduate
Format: Hardback
Publisher's Status: Active

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005). Daniel E. Johnson received his undergraduate degrees in chemistry and mathematics from North Park University in Chicago, Illinois. He received his doctoral degree in molecular biology from Princeton University under the mentorship of Dr. Mark A. Bothwell. His postdoctoral research was done under the mentorship of Dr. Lewis T. Williams at the University of California at San Francisco (UCSF). He joined the faculty at the University of Pittsburgh and the University of Pittsburgh Cancer Institute in 1993, where he served as Professor of Medicine and Scientific Director of the Acute Leukemia Working Group. In 2016, he moved to UCSF where he is currently Professor in the Department of Otolaryngology – Head and Neck Surgery. Dr. Johnson has served as a standing member on National Institutes of Health and American Cancer Society study sections and has been a Section Editor for the journal Leukemia since 2001. His research is focused on anti-cancer drug development and the elucidation of cell death and cell survival signaling pathways in head and neck cancer and leukemia. He has additional interests in the development of chemopreventive agents and strategies. Dr. Johnson places particular emphasis on translating laboratory findings to the clinic and has collaborated extensively with physician scientists to initiate and conduct clinical trials in head and neck cancer and acute myeloid leukemia. .